Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EU asked to investigate British drug lottery
MEP Chris Heaton-Harris has asked the Commission to look into UK drug distribution on the grounds that it breaks European anti-discrimination laws. Mr Heaton-Harris is defending a patient
MEP Chris Heaton-Harris has asked the Commission to look into UK drug distribution on the grounds that it breaks European anti-discrimination laws. Mr Heaton-Harris is defending a patient
The company also announced a median one-year survival rate of 17.6% in the Phase II population of mostly platinum-refractory and -resistant patients studied in this trial. Picoplatin, the
This approval represents the first regulatory approval for Celgene in Switzerland, and Revlimid represents the first oral therapy in Switzerland for multiple myeloma patients in more than 40
This sNDA includes the removal of a dosing recommendation, which limited Aloxi use to once per seven day interval, from the product's label. Data from several safety and
The glucagon receptor (GCGR) binds glucagon, a hormone that opposes the action of insulin. The Phase I trial of ISIS 325568 is designed to assess the drug's activity,
Diastolic heart failure(DHF) is a type of congestive heart failure (CHF). “We are pleased with the clinical progress of this additional indication for sitaxsentan,” said George Cole, president
More than 11,000 patients with type II diabetes took part in the study, which found that those who were treated with the combined therapy were 18% less likely
In previous pre-clinical trials, MIV-210 has demonstrated very potent activity against hepatitis B virus (HBV) and has good pharmacokinetic properties, according to the companies. MIV-210 belongs to the
The drug, SPP100, was approved by the FDA in the US in March 2007 under the trade name Tekturna and by the European Union under the trade name
Authorization of the acute coronary syndromes (ACS) indication was based on positive results from two pivotal Phase III trials including more than 32,000 patients that compared Arixtra (fondaparinux)